MX359639B - Metodos y composiciones para uso en tratamientos celulares. - Google Patents

Metodos y composiciones para uso en tratamientos celulares.

Info

Publication number
MX359639B
MX359639B MX2012000396A MX2012000396A MX359639B MX 359639 B MX359639 B MX 359639B MX 2012000396 A MX2012000396 A MX 2012000396A MX 2012000396 A MX2012000396 A MX 2012000396A MX 359639 B MX359639 B MX 359639B
Authority
MX
Mexico
Prior art keywords
methods
compositions
cellular therapies
therapies
cellular
Prior art date
Application number
MX2012000396A
Other languages
English (en)
Other versions
MX2012000396A (es
Inventor
Lombardo Eleuterio
Buscher Dirk
Original Assignee
Cellerix Sa Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellerix Sa Star filed Critical Cellerix Sa Star
Publication of MX2012000396A publication Critical patent/MX2012000396A/es
Publication of MX359639B publication Critical patent/MX359639B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se refiere a un citoblasto de mesenquina para usar en el tratamiento, modulación, disminución y/o profilaxis de un trastorno inflamatorio y/o inmunitario en donde el citoblasto de mesénquima es administrble al sistema linfático por inyección intralinfática. Y una composición farmaceúticamente comprende al citoblasto.
MX2012000396A 2009-07-09 2010-07-09 Metodos y composiciones para uso en tratamientos celulares. MX359639B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22427509P 2009-07-09 2009-07-09
PCT/IB2010/001968 WO2011004264A1 (en) 2009-07-09 2010-07-09 Methods and compositions for use in cellular therapies

Publications (2)

Publication Number Publication Date
MX2012000396A MX2012000396A (es) 2012-07-17
MX359639B true MX359639B (es) 2018-10-04

Family

ID=42782196

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000396A MX359639B (es) 2009-07-09 2010-07-09 Metodos y composiciones para uso en tratamientos celulares.

Country Status (19)

Country Link
US (1) US8679834B2 (es)
EP (2) EP3150703A1 (es)
JP (1) JP5892931B2 (es)
KR (1) KR101788885B1 (es)
CN (2) CN107007626A (es)
AU (1) AU2010269962B2 (es)
BR (1) BR112012000534A2 (es)
CA (1) CA2767300C (es)
DK (1) DK2451943T3 (es)
ES (1) ES2479542T3 (es)
HU (1) HUE031921T2 (es)
IL (1) IL217377A (es)
MX (1) MX359639B (es)
NZ (1) NZ597975A (es)
PL (1) PL2451943T3 (es)
PT (1) PT2451943T (es)
RU (1) RU2610427C2 (es)
SG (2) SG10201403758SA (es)
WO (1) WO2011004264A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
WO2011006029A1 (en) 2009-07-10 2011-01-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Artificial cell constructs for inducing immunological tolerance
US11090363B2 (en) 2009-07-10 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Vasoactive intestinal peptide release from microparticles
WO2012095743A2 (en) * 2011-01-12 2012-07-19 Cellerix Sa Methods and compositions for use in intralymphatic cellular therapies
TW202537630A (zh) 2011-11-30 2025-10-01 美商安斯泰來再生醫藥協會 利用血管母細胞產生間葉基質細胞之方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
CN104822384A (zh) * 2012-03-30 2015-08-05 南加州大学 用于间充质干细胞诱导的免疫调节的组合物和治疗方法
CN104471059B (zh) 2012-07-12 2018-04-17 珠海横琴爱姆斯坦生物科技有限公司 人胚胎干细胞衍生的间充质样干细胞、方法及其应用
WO2016098061A1 (en) 2014-12-18 2016-06-23 Pluristem Ltd. Methods and compositions for treating and preventing muscle wasting disorders
WO2016107563A1 (zh) * 2014-12-29 2016-07-07 西比曼生物科技（上海）有限公司 一种用于治疗上呼吸道疾病的脂肪间充质祖细胞复合物
CN107864627A (zh) 2015-03-23 2018-03-30 普拉里斯坦有限公司 包含粘附基质细胞的方法和组合物
CA3012741A1 (en) 2016-02-18 2017-08-24 Pluristem Ltd. Methods and compositions for treating cancer and neoplasms
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
IL269893B2 (en) 2017-05-15 2023-10-01 Stem Cell Medicine Ltd Treatment of multiple sclerosis with adipose-derived stem cells
CA3062964C (en) 2017-05-15 2024-11-12 Mapi Pharma Ltd. TREATMENT OF MULTIPLE SCLEROSIS WITH A LONG-ACTING GLATIRAMER AND ADIPE-DERIVED STEM CELLS
CN107281469A (zh) * 2017-07-17 2017-10-24 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
CN107349419A (zh) * 2017-07-17 2017-11-17 广东颜值科技有限公司 一种细胞组合物及其制备方法和应用
CN112912087A (zh) * 2018-09-14 2021-06-04 卢卡科学株式会社 线粒体向淋巴器官中的移植以及用于该移植的组合物
US11975030B2 (en) * 2019-03-19 2024-05-07 Figene, Llc Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
US20240000850A1 (en) * 2020-04-08 2024-01-04 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
AU2003293411B2 (en) * 2002-12-06 2010-10-28 Northwest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
MX342474B (es) 2005-09-23 2016-09-30 Cellerix Sl Poblaciones celulares con actividad inmunoreguladora, método de aislamiento y usos.
US8241621B2 (en) * 2006-12-18 2012-08-14 Medistem Laboratories Stem cell mediated treg activation/expansion for therapeutic immune modulation
AU2008287063B2 (en) * 2007-08-09 2013-10-24 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
EP2191835A4 (en) * 2007-09-07 2011-12-14 Japan Chem Res THERAPEUTIC AND PROPHYLACTIC AGENTS FOR ARTHRITIS
US20110150845A1 (en) * 2008-05-02 2011-06-23 Massachusetts Institute Of Technology Methods and compositions for modulating immunological tolerance
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells

Also Published As

Publication number Publication date
IL217377A (en) 2017-10-31
CA2767300C (en) 2020-01-07
DK2451943T3 (en) 2017-02-06
WO2011004264A1 (en) 2011-01-13
IL217377A0 (en) 2012-02-29
HUE031921T2 (en) 2017-08-28
KR20120051006A (ko) 2012-05-21
ES2479542T3 (es) 2017-05-26
CA2767300A1 (en) 2011-01-13
US20120308585A1 (en) 2012-12-06
PL2451943T3 (pl) 2017-04-28
EP3150703A1 (en) 2017-04-05
NZ597975A (en) 2014-06-27
EP2451943B1 (en) 2016-11-23
KR101788885B1 (ko) 2017-10-20
SG10201403758SA (en) 2014-10-30
JP5892931B2 (ja) 2016-03-23
EP2451943A1 (en) 2012-05-16
BR112012000534A2 (pt) 2017-06-13
ES2479542T1 (es) 2014-08-20
RU2012104529A (ru) 2013-08-20
CN107007626A (zh) 2017-08-04
AU2010269962B2 (en) 2016-04-14
AU2010269962A1 (en) 2012-03-01
CN102549147A (zh) 2012-07-04
SG177582A1 (en) 2012-03-29
PT2451943T (pt) 2017-01-20
MX2012000396A (es) 2012-07-17
JP2012532859A (ja) 2012-12-20
RU2610427C2 (ru) 2017-02-10
US8679834B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MX2013002048A (es) Conjugados, particulas, composiciones y metodos relacionados.
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
MY181898A (en) Heterocyclic compounds and uses thereof
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
TN2012000161A1 (en) Spiro-oxindole mdm2 antagonists
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
PH12014501108A1 (en) Anti-il-36r antibodies
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
TN2012000414A1 (en) Forms of rifaximin and uses thereof
IN2012DN02046A (es)
MX2011010012A (es) NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
MX2013012184A (es) Composiciones formadoras de gel in situ.
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
MY161601A (en) Films and compositions comprising the same
PH12013500500A1 (en) Fused heteroaryls and their uses
WO2012095743A3 (en) Adipose -derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.
IN2012DN03404A (es)
WO2012016026A3 (en) Electrolarynx devices and uses thereof
MX2013008559A (es) Derivados de leptina.

Legal Events

Date Code Title Description
FG Grant or registration